Cited 3 times in
Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 신동호 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2017-11-02T08:09:48Z | - |
dc.date.available | 2017-11-02T08:09:48Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154150 | - |
dc.description.abstract | PURPOSE: To compare the 1-year outcomes of a durable polymer Zotarolimus-eluting stent (ZES) versus a biodegradable polymer Biolimus-eluting stent (BES) in patients undergoing percutaneous coronary intervention. MATERIALS AND METHODS: A total of 2083 patients from 2 different registries, 1125 treated with BES in NOBORI registry and 858 received ZES in CONSTANT registry were included in this study. Clinical outcomes were compared with the use of propensity score matching (PSM). The primary endpoint was a composite of major adverse cardiovascular and cerebrovascular events (MACCEs) including cardiac death, myocardial infarction, clinically driven target lesion revascularization and stroke. Secondary end points were individual components of MACCEs as well as the incidence of stent thrombosis at 1-year follow-up. RESULTS: After PSM, 699 matched pairs of patients (n=1398) showed no significant difference between BES and ZES in the risk of composite MACCEs at 1 year (2.6% vs. 1.7%; p=0.36). Cardiac death was not statistically different between groups (0.7% vs. 0.4%, p=0.73). Target lesion revascularization rate was also similar between BES and ZES (1.1% vs. 0.7%, p=0.579). Non-Q wave myocardial infarction, as well as target-vessel revascularization rate, was similar between the two groups (0.14% for BES and 0.72% for ZES). Both stent types were excellent with no cases of stent thrombosis and rate of Q wave myocardial infarction reported during the follow-up period. CONCLUSION: In this cohort of patients treated with BES or ZES, the rate of MACCEs at 1 year was low and significantly not different between both groups. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Absorbable Implants | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cardiovascular Agents/administration & dosage* | - |
dc.subject.MESH | Coronary Artery Disease/diagnosis | - |
dc.subject.MESH | Coronary Artery Disease/therapy* | - |
dc.subject.MESH | Drug-Eluting Stents/adverse effects* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/etiology | - |
dc.subject.MESH | Percutaneous Coronary Intervention/adverse effects | - |
dc.subject.MESH | Polymers | - |
dc.subject.MESH | Propensity Score* | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Sirolimus/administration & dosage* | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Ayman Tantawy | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Dong-Ho Shin,1 Jung-Sun Kim,1 Byeong-Keuk Kim,1 Young-Guk Ko,1 Donghoon Choi,1 Yangsoo Jang,1 and Meong-Ki Hongcorresponding author1 | - |
dc.identifier.doi | 10.3349/ymj.2017.58.2.290 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A00127 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 28120558 | - |
dc.subject.keyword | Percutaneous coronary intervention | - |
dc.subject.keyword | biolimus A9 | - |
dc.subject.keyword | drug-eluting stents | - |
dc.subject.keyword | polymers | - |
dc.subject.keyword | propensity score | - |
dc.subject.keyword | zotarolimus | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.alternativeName | Shin, Dong Ho | - |
dc.contributor.alternativeName | Ahn, Chul Min | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | Shin, Dong Ho | - |
dc.contributor.affiliatedAuthor | Ahn, Chul Min | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Ko, Young Guk | - |
dc.citation.title | Yonsei Medical Journal | - |
dc.citation.volume | 58 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 290 | - |
dc.citation.endPage | 295 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.58(2) : 290-295, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42112 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.